Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis

D. C. Metz, W. J. Bochenek, Richard Aaronson, James L. Achord, Dennis Avner, Jose Behar, Mark Blitstein, Saul Feldman, Ralph A. Giannella, William V. Harford, Vernon Hee, James V. Jones, Peter J. Karras, David Kogut, Robert Kornfield, Thomas Kovacs, Thomas Meister, David Metz, Philip Miner, John OrchardDaniel Pambianco, Anirudh Rai, Richard Redinger, Dennis Riff, John Rodgers, Stanley Rosenberg, Alan Safdi, Paul Schlesinger, Howard I. Schwartz, William Snape, James Wagonfeld, Steven Wilkofsky, Barry D. Winston, Lawrence Wruble, Wallace Wu

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objectives: To compare the safety and efficacy of pantoprazole with ranitidine for the maintenance of endoscopically documented healed (grade 0 or 1) erosive oesophagitis. Methods: Patients (371) were randomly assigned to receive pantoprazole 10, 20 or 40 mg or ranitidine 150 mg. Endoscopies were performed after 1, 3, 6 and 12 months or when symptoms suggesting relapse (grade = 2) developed. Gastric biopsies were obtained at baseline and on at least one postbaseline visit. Symptom-free days and Gelusil use were assessed. Results: Pantoprazole was significantly (P < 0.001) more effective in maintaining erosive oesophagitis healing. After 12 months. 33%, 40%, 68% and 82% of patients remained healed for the ranitidine and pantoprazole 10, 20 and 40 mg groups, respectively. Daytime and night-time heartburn were eliminated in > 90% of days for the pantoprazole 40 mg group. Gelusil use was significantly lower with pantoprazole 20 and 40 mg than with ranitidine (P < 0.02) during the first 9 months. Conclusions: Twelve months of maintenance therapy with pantoprazole (10-40 mg once daily) was superior to ranitidine (150 mg twice daily) in maintaining erosive oesophagitis healing. Pantoprazole 40 mg provided the most consistent efficacy and was well tolerated.

Original languageEnglish (US)
Pages (from-to)155-164
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Esophagitis
Ranitidine
Recurrence
Therapeutics
pantoprazole
Endoscopy
Stomach
Maintenance
Biopsy
Safety

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Metz, D. C., Bochenek, W. J., Aaronson, R., Achord, J. L., Avner, D., Behar, J., ... Wu, W. (2003). Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. Alimentary Pharmacology and Therapeutics, 17(1), 155-164. https://doi.org/10.1046/j.1365-2036.2003.01410.x

Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. / Metz, D. C.; Bochenek, W. J.; Aaronson, Richard; Achord, James L.; Avner, Dennis; Behar, Jose; Blitstein, Mark; Feldman, Saul; Giannella, Ralph A.; Harford, William V.; Hee, Vernon; Jones, James V.; Karras, Peter J.; Kogut, David; Kornfield, Robert; Kovacs, Thomas; Meister, Thomas; Metz, David; Miner, Philip; Orchard, John; Pambianco, Daniel; Rai, Anirudh; Redinger, Richard; Riff, Dennis; Rodgers, John; Rosenberg, Stanley; Safdi, Alan; Schlesinger, Paul; Schwartz, Howard I.; Snape, William; Wagonfeld, James; Wilkofsky, Steven; Winston, Barry D.; Wruble, Lawrence; Wu, Wallace.

In: Alimentary Pharmacology and Therapeutics, Vol. 17, No. 1, 01.01.2003, p. 155-164.

Research output: Contribution to journalArticle

Metz, DC, Bochenek, WJ, Aaronson, R, Achord, JL, Avner, D, Behar, J, Blitstein, M, Feldman, S, Giannella, RA, Harford, WV, Hee, V, Jones, JV, Karras, PJ, Kogut, D, Kornfield, R, Kovacs, T, Meister, T, Metz, D, Miner, P, Orchard, J, Pambianco, D, Rai, A, Redinger, R, Riff, D, Rodgers, J, Rosenberg, S, Safdi, A, Schlesinger, P, Schwartz, HI, Snape, W, Wagonfeld, J, Wilkofsky, S, Winston, BD, Wruble, L & Wu, W 2003, 'Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis', Alimentary Pharmacology and Therapeutics, vol. 17, no. 1, pp. 155-164. https://doi.org/10.1046/j.1365-2036.2003.01410.x
Metz, D. C. ; Bochenek, W. J. ; Aaronson, Richard ; Achord, James L. ; Avner, Dennis ; Behar, Jose ; Blitstein, Mark ; Feldman, Saul ; Giannella, Ralph A. ; Harford, William V. ; Hee, Vernon ; Jones, James V. ; Karras, Peter J. ; Kogut, David ; Kornfield, Robert ; Kovacs, Thomas ; Meister, Thomas ; Metz, David ; Miner, Philip ; Orchard, John ; Pambianco, Daniel ; Rai, Anirudh ; Redinger, Richard ; Riff, Dennis ; Rodgers, John ; Rosenberg, Stanley ; Safdi, Alan ; Schlesinger, Paul ; Schwartz, Howard I. ; Snape, William ; Wagonfeld, James ; Wilkofsky, Steven ; Winston, Barry D. ; Wruble, Lawrence ; Wu, Wallace. / Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. In: Alimentary Pharmacology and Therapeutics. 2003 ; Vol. 17, No. 1. pp. 155-164.
@article{3fa9fe54f76a492e8aa5e4e8bad429e0,
title = "Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis",
abstract = "Objectives: To compare the safety and efficacy of pantoprazole with ranitidine for the maintenance of endoscopically documented healed (grade 0 or 1) erosive oesophagitis. Methods: Patients (371) were randomly assigned to receive pantoprazole 10, 20 or 40 mg or ranitidine 150 mg. Endoscopies were performed after 1, 3, 6 and 12 months or when symptoms suggesting relapse (grade = 2) developed. Gastric biopsies were obtained at baseline and on at least one postbaseline visit. Symptom-free days and Gelusil use were assessed. Results: Pantoprazole was significantly (P < 0.001) more effective in maintaining erosive oesophagitis healing. After 12 months. 33{\%}, 40{\%}, 68{\%} and 82{\%} of patients remained healed for the ranitidine and pantoprazole 10, 20 and 40 mg groups, respectively. Daytime and night-time heartburn were eliminated in > 90{\%} of days for the pantoprazole 40 mg group. Gelusil use was significantly lower with pantoprazole 20 and 40 mg than with ranitidine (P < 0.02) during the first 9 months. Conclusions: Twelve months of maintenance therapy with pantoprazole (10-40 mg once daily) was superior to ranitidine (150 mg twice daily) in maintaining erosive oesophagitis healing. Pantoprazole 40 mg provided the most consistent efficacy and was well tolerated.",
author = "Metz, {D. C.} and Bochenek, {W. J.} and Richard Aaronson and Achord, {James L.} and Dennis Avner and Jose Behar and Mark Blitstein and Saul Feldman and Giannella, {Ralph A.} and Harford, {William V.} and Vernon Hee and Jones, {James V.} and Karras, {Peter J.} and David Kogut and Robert Kornfield and Thomas Kovacs and Thomas Meister and David Metz and Philip Miner and John Orchard and Daniel Pambianco and Anirudh Rai and Richard Redinger and Dennis Riff and John Rodgers and Stanley Rosenberg and Alan Safdi and Paul Schlesinger and Schwartz, {Howard I.} and William Snape and James Wagonfeld and Steven Wilkofsky and Winston, {Barry D.} and Lawrence Wruble and Wallace Wu",
year = "2003",
month = "1",
day = "1",
doi = "10.1046/j.1365-2036.2003.01410.x",
language = "English (US)",
volume = "17",
pages = "155--164",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis

AU - Metz, D. C.

AU - Bochenek, W. J.

AU - Aaronson, Richard

AU - Achord, James L.

AU - Avner, Dennis

AU - Behar, Jose

AU - Blitstein, Mark

AU - Feldman, Saul

AU - Giannella, Ralph A.

AU - Harford, William V.

AU - Hee, Vernon

AU - Jones, James V.

AU - Karras, Peter J.

AU - Kogut, David

AU - Kornfield, Robert

AU - Kovacs, Thomas

AU - Meister, Thomas

AU - Metz, David

AU - Miner, Philip

AU - Orchard, John

AU - Pambianco, Daniel

AU - Rai, Anirudh

AU - Redinger, Richard

AU - Riff, Dennis

AU - Rodgers, John

AU - Rosenberg, Stanley

AU - Safdi, Alan

AU - Schlesinger, Paul

AU - Schwartz, Howard I.

AU - Snape, William

AU - Wagonfeld, James

AU - Wilkofsky, Steven

AU - Winston, Barry D.

AU - Wruble, Lawrence

AU - Wu, Wallace

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Objectives: To compare the safety and efficacy of pantoprazole with ranitidine for the maintenance of endoscopically documented healed (grade 0 or 1) erosive oesophagitis. Methods: Patients (371) were randomly assigned to receive pantoprazole 10, 20 or 40 mg or ranitidine 150 mg. Endoscopies were performed after 1, 3, 6 and 12 months or when symptoms suggesting relapse (grade = 2) developed. Gastric biopsies were obtained at baseline and on at least one postbaseline visit. Symptom-free days and Gelusil use were assessed. Results: Pantoprazole was significantly (P < 0.001) more effective in maintaining erosive oesophagitis healing. After 12 months. 33%, 40%, 68% and 82% of patients remained healed for the ranitidine and pantoprazole 10, 20 and 40 mg groups, respectively. Daytime and night-time heartburn were eliminated in > 90% of days for the pantoprazole 40 mg group. Gelusil use was significantly lower with pantoprazole 20 and 40 mg than with ranitidine (P < 0.02) during the first 9 months. Conclusions: Twelve months of maintenance therapy with pantoprazole (10-40 mg once daily) was superior to ranitidine (150 mg twice daily) in maintaining erosive oesophagitis healing. Pantoprazole 40 mg provided the most consistent efficacy and was well tolerated.

AB - Objectives: To compare the safety and efficacy of pantoprazole with ranitidine for the maintenance of endoscopically documented healed (grade 0 or 1) erosive oesophagitis. Methods: Patients (371) were randomly assigned to receive pantoprazole 10, 20 or 40 mg or ranitidine 150 mg. Endoscopies were performed after 1, 3, 6 and 12 months or when symptoms suggesting relapse (grade = 2) developed. Gastric biopsies were obtained at baseline and on at least one postbaseline visit. Symptom-free days and Gelusil use were assessed. Results: Pantoprazole was significantly (P < 0.001) more effective in maintaining erosive oesophagitis healing. After 12 months. 33%, 40%, 68% and 82% of patients remained healed for the ranitidine and pantoprazole 10, 20 and 40 mg groups, respectively. Daytime and night-time heartburn were eliminated in > 90% of days for the pantoprazole 40 mg group. Gelusil use was significantly lower with pantoprazole 20 and 40 mg than with ranitidine (P < 0.02) during the first 9 months. Conclusions: Twelve months of maintenance therapy with pantoprazole (10-40 mg once daily) was superior to ranitidine (150 mg twice daily) in maintaining erosive oesophagitis healing. Pantoprazole 40 mg provided the most consistent efficacy and was well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0037253272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037253272&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2003.01410.x

DO - 10.1046/j.1365-2036.2003.01410.x

M3 - Article

C2 - 12492745

AN - SCOPUS:0037253272

VL - 17

SP - 155

EP - 164

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 1

ER -